Working… Menu

AIR (Artificial Implant for Medial Meniscus Replacement) Study (AIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03696836
Recruitment Status : Active, not recruiting
First Posted : October 5, 2018
Last Update Posted : July 16, 2020
Information provided by (Responsible Party):
ATRO Medical B.V.

Brief Summary:
The AIR Study is a multi-center, prospective, interventional clinical trial with the objective to evaluate the safety and performance of the Trammpolin® meniscus prosthesis system.

Condition or disease Intervention/treatment Phase
Meniscectomy Osteo Arthritis Knee Device: Trammpolin® meniscus prosthesis Not Applicable

Detailed Description:

The Trammpolin® meniscus prosthesis is intended to replace the native medial meniscus to provide pain relief in the medial compartment of the knee joint, when this is caused by medial partial meniscectomy.

Patients who meet the inclusion/exclusion criteria and who are implanted with the Trammpolin® meniscus prosthesis will be followed for 2 years. The patient reported outcome measures for knee pain and function, and knee clinical condition by MRI and X-ray is assessed post-operative compared to pre-operative.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Medial Knee Joint Pain With the Trammpolin® Meniscus Prosthesis
Actual Study Start Date : October 11, 2018
Estimated Primary Completion Date : January 7, 2021
Estimated Study Completion Date : January 7, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Artificial Limbs

Arm Intervention/treatment
Experimental: Trammpolin® meniscus prosthesis
The patients will be implanted with the Trammpolin® meniscus prosthesis
Device: Trammpolin® meniscus prosthesis
Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement

Primary Outcome Measures :
  1. Knee injury and Osteoarthritis Outcome Score (KOOS) Pain sub-scale [ Time Frame: 24 Months ]
    Performance of the Trammpolin® meniscus prosthesis in improving pain

  2. Trammpolin® meniscus prosthesis device related complications [ Time Frame: 24 Months ]
    The nature and frequency of all adverse events observed during the study

Secondary Outcome Measures :
  1. KOOS Pain sub-scale [ Time Frame: 6 Weeks; 3, 6 and 12 Months ]
    KOOS Pain sub-scale

  2. Overall KOOS scale [ Time Frame: 6 Weeks; 3, 6, 12 and 24 Months ]
    Overall KOOS scale

  3. Lysholm scale [ Time Frame: 6 Weeks; 3, 6, 12 and 24 Months ]
    Lysholm scale

  4. IKDC objective scale [ Time Frame: 6 Weeks; 3, 6, 12 and 24 Months ]
    IKDC objective scale

  5. Knee X-ray [ Time Frame: 6 Weeks; 12 and 24 Months ]
    Joint space measurement

  6. Knee MRI [ Time Frame: 12 and 24 Months ]
    Cartilage damage and extrusion

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Has medial compartment joint pain with > 6 months ago a medial partial meniscectomy as confirmed by patient history and MRI
  2. Has a KOOS Pain of ≤ 75 (100 being no pain and the highest attainable score)
  3. Is between age 30 and 65 years (inclusive) at the time of screening
  4. Has neutral alignment ± 5° of the mechanical axis, i.e., the angle formed by a line drawn from the center of the femoral head to the medial tibial spine and a line drawn from the medial tibial spine to the center of the ankle joint, as confirmed by X-ray
  5. Is willing to be implanted with the Trammpolin® meniscus prosthesis.
  6. Is able to do the study required follow up visits, questionnaires, X-rays, CT-scans, and MRI's
  7. Is able and willing to understand and sign the study Informed Consent Form
  8. Is able to read and understand the national language of the country in which the relevant clinical site is located

Exclusion Criteria:

  1. Has a symptomatic knee because of a tear that could be addressed by a repeat partial meniscectomy
  2. Has evidence of a modified Outerbridge Grade IV cartilage loss on the medial tibial plateau or femoral condyle that potentially could contact a Trammpolin® meniscus prosthesis (e.g., a focal lesion > 0.5 cm2 correlating to a circular defect of > 8 mm in diameter)
  3. Has lateral compartment pain and Grade III or Grade IV modified Outerbridge cartilage score in the lateral compartment
  4. Has a varus or valgus knee deformity of > 5° requiring a tibial or femoral osteotomy
  5. Has a varus alignment that is not passively correctable
  6. Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL)
  7. Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment
  8. Has patellar compartment pain and Grade III or Grade IV modified Outerbridge cartilage score in the patellar compartment.
  9. Compared to a normal knee, has obvious radiological evidence of medial femoral squaring, anatomical variance in the medial tibial plateau, or irregularly shaped cartilage surface
  10. Had an ACL reconstruction performed < 9 months prior to surgery
  11. Has a BMI > 32.5 at the time of screening
  12. Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or ceramic, not including the Trammpolin® meniscus prosthesis
  13. Has a knee flexion contracture > 10°
  14. Has flexion < 90°
  15. Had a previous medial femoral condyle surgery (not including microfracture) or High Tibial Osteotomy (HTO)
  16. Has insufficiency fractures or avascular necrosis of the medial compartment
  17. Has an active infection or tumor (local or systemic)
  18. Has any type of knee joint inflammatory disease including Sjogren's syndrome
  19. Has neuropathic knee osteoarthropathy, also known as Charcot joint
  20. Has any medical condition that does not allow possible arthroscopy of the knee
  21. Has neurological deficit (sensory, motor, or reflex)
  22. Is currently involved in another investigation of the lower extremity
  23. Anticipates having another lower extremity surgery during the study period
  24. Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura)
  25. Has received any corticosteroid knee injections ≤ 3 months prior to surgery
  26. Has chondrocalcinosis
  27. Has proven osteoporosis
  28. Is on immunostimulating or immunosuppressing agents
  29. Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or KOOS (e.g. have a leg length discrepancy > 2.5 cm [1 inch], causing a noticeable limp)
  30. Is a female who is lactating, expecting, or is intending to become pregnant during the study period
  31. Is an active smoker
  32. Is mentally incapacitated (incapable of appraising or controlling conduct) or have mental disability (e.g., dementia or Alzheimer's)
  33. Is a prisoner
  34. Has a condition or be in a situation that, in the Investigator's opinion, may confound the study results, or may interfere significantly with the subject's participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03696836

Layout table for location information
Maastricht UMC+
Maastricht, Netherlands, 6229 HX
Radboud UMC
Nijmegen, Netherlands, 6525 GA
Sint Maartenskliniek
Ubbergen, Netherlands, 6574 NA
Sponsors and Collaborators
ATRO Medical B.V.
Layout table for additonal information
Responsible Party: ATRO Medical B.V. Identifier: NCT03696836    
Other Study ID Numbers: AM-001
First Posted: October 5, 2018    Key Record Dates
Last Update Posted: July 16, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases